Akèy › Distrofi Mizik
Etid klinik pou Distrofi Mizik ap rekrite nan Etazini
27 etid pou Distrofi Mizik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Washington, DC8 etid
- Sacramento, CA4 etid
- Boston, MA4 etid
- Chicago, IL4 etid
- Gainesville, FL3 etid
- Mountain View, CA3 etid
- Little Rock, AR3 etid
- Durham, NC3 etid
Pa eta
- Arkansas3 etid
- Distrik Columbia4 etid
- Florid3 etid
- Illinois4 etid
- Kalifòni6 etid
- Maryland5 etid
- Massachusetts4 etid
- New York3 etid
- North Carolina4 etid
- Texas4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Study of Inherited Neurological Disorders
Ap rekriteEtid obsèvasyon
Laj 2 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT00004568Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
Ap rekriteEtid obsèvasyon
Laj 2 ak plis · Gason · Mizajou Sep 24, 2026 · NCT06564974Investigational Use of Neuromuscular Ultrasound
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 110 · Tout sèks · Mizajou Sep 17, 2026 · NCT05237973Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Ap rekriteEtid obsèvasyon
Laj 18 a 70 · Tout sèks · Mizajou Sep 4, 2026 · NCT07700225Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
Ap rekrite
Laj 18 a 80 · Tout sèks · Mizajou Sep 2, 2026 · NCT07521930Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
Ap rekriteFaz 1
Laj 8 a 18 · Gason · Mizajou Aug 24, 2026 · NCT07172971Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients
Ap rekrite
Laj 6 ak plis · Gason · Mizajou Aug 17, 2026 · NCT07766980Once Weekly Infant Corticosteroid Trial for DMD
Ap rekriteFaz 4
1 Month – 30 Months · Gason · Mizajou Aug 14, 2026 · NCT05412394Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults
Ap rekriteEtid obsèvasyon
Laj 5 a 25 · Tout sèks · Mizajou Jul 23, 2026 · NCT06998134A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy
Ap rekriteEtid obsèvasyon
Laj 6 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT07127978PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)
Ap rekriteFaz 1/2
Laj 2 a 7 · Gason · Mizajou Jun 23, 2026 · NCT07429240Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
Ap rekrite
Laj 18 a 80 · Tout sèks · Mizajou Jun 2, 2026 · NCT05724173BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
Ap rekrite
Laj 18 a 80 · Tout sèks · Mizajou Jun 1, 2026 · NCT00912041Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
Ap rekriteFaz 3
Laj 4 a 18 · Gason · Mizajou May 27, 2026 · NCT07608432Duchenne Electronic Health Record Study
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 27, 2026 · NCT07609394Vasodilator and Exercise Study for DMD (VASO-REx)
Ap rekriteFaz 2
Laj 6 ak plis · Gason · Mizajou May 15, 2026 · NCT06290713Nomad P-KAFO Study
Ap rekrite
Laj 18 a 89 · Tout sèks · Mizajou May 11, 2026 · NCT05644522The Duchenne Registry
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 8, 2026 · NCT02069756ECoG BMI for Motor and Speech Control
Ap rekrite
Laj 21 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT03698149Muscle Health Measurements Using Electrical Impedance Myography
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 89 · Tout sèks · Mizajou Apr 3, 2026 · NCT07502989Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Jan 23, 2026 · NCT07362875Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
Ap rekrite
Laj 18 a 80 · Tout sèks · Mizajou Dec 1, 2025 · NCT06094205Long-Term Development of Muscular Dystrophy Outcome Assessments
Ap rekriteEtid obsèvasyon
Laj 6 a 50 · Tout sèks · Mizajou Nov 18, 2025 · NCT05989620Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders
Ap rekrite
Laj 3 a 17 · Tout sèks · Mizajou Oct 27, 2025 · NCT05726591Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Oct 15, 2025 · NCT00082108Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.